IL158124A0 - Leishmania vaccines - Google Patents

Leishmania vaccines

Info

Publication number
IL158124A0
IL158124A0 IL15812402A IL15812402A IL158124A0 IL 158124 A0 IL158124 A0 IL 158124A0 IL 15812402 A IL15812402 A IL 15812402A IL 15812402 A IL15812402 A IL 15812402A IL 158124 A0 IL158124 A0 IL 158124A0
Authority
IL
Israel
Prior art keywords
leishmania
vaccines
leishmania vaccines
Prior art date
Application number
IL15812402A
Other languages
English (en)
Original Assignee
Univ Mcgill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Mcgill filed Critical Univ Mcgill
Publication of IL158124A0 publication Critical patent/IL158124A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/002Protozoa antigens
    • A61K39/008Leishmania antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55516Proteins; Peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/20011Papillomaviridae
    • C12N2710/20022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL15812402A 2001-03-29 2002-03-27 Leishmania vaccines IL158124A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27942301P 2001-03-29 2001-03-29
PCT/CA2002/000437 WO2002078735A2 (fr) 2001-03-29 2002-03-27 Vaccins contre la leishmania

Publications (1)

Publication Number Publication Date
IL158124A0 true IL158124A0 (en) 2004-03-28

Family

ID=23068901

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15812402A IL158124A0 (en) 2001-03-29 2002-03-27 Leishmania vaccines

Country Status (7)

Country Link
US (1) US20040170636A1 (fr)
EP (1) EP1372705A2 (fr)
BR (1) BR0208532A (fr)
CA (1) CA2442298A1 (fr)
IL (1) IL158124A0 (fr)
MX (1) MXPA03008832A (fr)
WO (1) WO2002078735A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10314412A1 (de) * 2003-03-28 2004-10-14 Genovac Ag Genetische Immunisierung mit multiplen Expressionskonstrukten zur Herstellung von monoklonalen Antikörpern
BRPI0603490B1 (pt) 2006-07-21 2018-04-24 Universidade Federal De Minas Gerais Vacina recombinante contra a leishmaniose visceral canina
US8968749B2 (en) 2006-07-21 2015-03-03 Universidade Federal De Minas Gerais—Ufmg Vaccine composition and immunization method
BRPI0800485B8 (pt) * 2008-01-17 2021-05-25 Univ Minas Gerais vetores virais recombinantes, composição vacinal para leishmaniose e método de vacinação para leishmaniose
US8410258B2 (en) 2008-05-21 2013-04-02 Infections Disease Research Institute Recombinant polyprotein vaccines for the treatment and diagnosis of leishmaniasis
ES2528928T3 (es) * 2008-05-21 2015-02-13 Infectious Disease Research Institute Vacunas de poliproteína recombinante para el tratamiento y diagnóstico de leishmaniosis
BR112020016474A2 (pt) * 2018-02-13 2020-12-15 University Of Iowa Research Foundation Imunoterapia de leishmaniose
US10898460B1 (en) 2018-07-20 2021-01-26 University Of South Florida Leishmania inhibitors
ES2795149B2 (es) 2020-06-08 2022-07-04 Univ Madrid Complutense Quimera sintetica multiepitopica como vacuna y tratamiento frente a leishmaniosis en mamiferos

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE236252T1 (de) * 1993-09-03 2003-04-15 Univ Mcgill Differentiell exprimierte leishmania gene und proteinen
CA2366462C (fr) * 1998-12-04 2011-08-09 University Of Manitoba Procedure d'immunisation en deux etapes contre l'infection parchlamydia

Also Published As

Publication number Publication date
MXPA03008832A (es) 2004-05-05
WO2002078735A2 (fr) 2002-10-10
WO2002078735A3 (fr) 2003-04-10
CA2442298A1 (fr) 2002-10-10
EP1372705A2 (fr) 2004-01-02
BR0208532A (pt) 2005-01-18
US20040170636A1 (en) 2004-09-02

Similar Documents

Publication Publication Date Title
HUP0402259A3 (en) Vaccines
AU2002336760A8 (en) Mutable vaccines
HUP0402471A3 (en) Vaccine
IL155282A0 (en) Vaccines
GB0407935D0 (en) Vaccine
IL157498A0 (en) Vaccine
EP1423141A4 (fr) Vaccin
GB0306611D0 (en) Novel vaccine
GB0121171D0 (en) Vaccine
IL158124A0 (en) Leishmania vaccines
HUP0303878A3 (en) Smallpox vaccine
EP1429615A4 (fr) Vaccins par voie orale
GB0105238D0 (en) Vaccines
GB0108534D0 (en) Retaining means
GB0004533D0 (en) Vaccines
AU2002244589A1 (en) Leishmania vaccines
GB0113552D0 (en) Vaccines
GB2376939B (en) Retaining means
GB0129338D0 (en) Vaccination
GB0103867D0 (en) Vaccine
GB0106589D0 (en) Vaccine
GB0130823D0 (en) Vaccine
GB0124137D0 (en) Vaccine
GB0115496D0 (en) Vaccine
GB0128312D0 (en) Vaccine